{"id":20979,"date":"2023-11-02T10:06:36","date_gmt":"2023-11-02T09:06:36","guid":{"rendered":"https:\/\/ggba.swiss\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/"},"modified":"2023-11-02T10:10:31","modified_gmt":"2023-11-02T09:10:31","slug":"lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/","title":{"rendered":"L’EPFL et Novochizol collaborent \u00e0 la conception d’immunoth\u00e9rapies plus efficaces"},"content":{"rendered":"\n

Novochizol<\/a> est une start-up innovante situ\u00e9e sur le campus des sciences de la vie BioArk<\/a> \u00e0 Monthey (canton du Valais). Elle est sp\u00e9cialis\u00e9e dans la transformation du chitosane – un biopolym\u00e8re naturel – en Novochizol, une technologie qui am\u00e9liore consid\u00e9rablement les propri\u00e9t\u00e9s des chitosanes standard. Cette innovation fait du Novochizol une plateforme polyvalente dans divers secteurs, notamment l’industrie pharmaceutique, la biotechnologie et l’agriculture, en raison de sa capacit\u00e9 \u00e0 am\u00e9liorer les syst\u00e8mes d’administration de m\u00e9dicaments, notamment en facilitant l’administration locale de traitements directement sur les sites de la maladie, avec une exposition syst\u00e9mique minimale.<\/p>\n\n\n\n

Le Laboratoire de Biomat\u00e9riaux pour l’Immuno-ing\u00e9nierie<\/a> de l’EPFL, dirig\u00e9 par le Professeur Li Tang, travaille de concert avec Novochizol SA. Le laboratoire est \u00e0 la pointe de l’immuno-ing\u00e9nierie, un domaine interdisciplinaire qui associe les complexit\u00e9s des r\u00e9ponses immunitaires \u00e0 des techniques de bio-ing\u00e9nierie de pointe. Leur mission est de d\u00e9velopper de nouvelles th\u00e9rapies efficaces contre le cancer et d’autres maladies en manipulant de mani\u00e8re complexe des \u00e9l\u00e9ments m\u00e9taboliques, cellulaires et m\u00e9caniques afin de moduler l’immunit\u00e9 avec pr\u00e9cision.<\/p>\n\n\n\n

Dans leur qu\u00eate de rem\u00e8des contre le cancer, l’\u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne et Novochizol se lancent dans une entreprise commune prometteuse pour concevoir des immunoth\u00e9rapies d’une s\u00e9curit\u00e9 et d’une efficacit\u00e9 sup\u00e9rieures. Soutenu par Innosuisse, le projet a obtenu un budget de CHF 1,1 million, dont CHF 498’000 proviennent d’une bourse d’Innosuisse, ce qui souligne la confiance dans le potentiel de ce projet \u00e0 faire des perc\u00e9es significatives contre les cancers.<\/p>\n\n\n\n

L’initiative de recherche de trois ans explorera les capacit\u00e9s des nanoparticules de Novochizol. Celles-ci sont con\u00e7ues pour transporter en toute s\u00e9curit\u00e9 des doses puissantes d’agents anticanc\u00e9reux tels que des cytokines et des inhibiteurs de points de contr\u00f4le immunitaire directement dans les tumeurs. L’utilisation innovante de Novochizol vise \u00e0 surmonter les limites actuelles des immunoth\u00e9rapies, en garantissant que les agents actifs restent prot\u00e9g\u00e9s et localis\u00e9s, r\u00e9duisant ainsi le risque de toxicit\u00e9s syst\u00e9miques.<\/p>\n\n\n\n

Red\u00e9finir les paradigmes de traitement en oncologie<\/h4>\n\n\n\n

\u00ab\u00a0D\u00e9livrer des cytokines et des inhibiteurs de points de contr\u00f4le immunitaire dans les tumeurs \u00e0 l’aide des nanoparticules de Novochizol pourrait red\u00e9finir les paradigmes de traitement en oncologie\u00a0\u00bb, a d\u00e9clar\u00e9 le Professeur Li Tang. La collaboration avec Novochizol pourrait non seulement transformer les traitements contre le cancer, mais aussi s’\u00e9tendre \u00e0 diverses conditions m\u00e9dicales qui b\u00e9n\u00e9ficient de l’administration localis\u00e9e de m\u00e9dicaments.<\/p>\n\n\n\n

Gr\u00e2ce \u00e0 ce partenariat, l’adoption de Novochizol pourrait acc\u00e9l\u00e9rer de nombreux projets de d\u00e9veloppement de m\u00e9dicaments par des tiers, ce qui pourrait aider des millions de patients dans le monde.<\/p>\n\n\n\n

La synergie entre l’expertise en immuno-ing\u00e9nierie de l’EPFL et le nouveau syst\u00e8me de distribution de nanoparticules de Novochizol incarnent l’esprit pionnier au c\u0153ur de la recherche m\u00e9dicale moderne. Gr\u00e2ce \u00e0 l’impulsion financi\u00e8re d’Innosuisse, cette collaboration pourrait ouvrir la voie \u00e0 des traitements anticanc\u00e9reux plus efficaces et plus adapt\u00e9s aux patients.<\/p>\n","protected":false},"excerpt":{"rendered":"

Une collaboration entre le Laboratoire de Biomat\u00e9riaux pour l’Immuno-ing\u00e9nierie de l’EPFL et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer.<\/p>\n","protected":false},"author":6,"featured_media":20975,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1162,1148,1140,1141,1142,1168],"class_list":["post-20979","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-education-en-fr","tag-financing-fr-2","tag-oncology-fr-2","tag-personalized-medicine-fr-2","tag-rd-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"\nEPFL et Novochizol con\u00e7oivent des immunoth\u00e9rapies ensemble<\/title>\n<meta name=\"description\" content=\"Une collaboration entre le l'EPFL et et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer par le biais de nouvelles immunoth\u00e9rapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EPFL et Novochizol con\u00e7oivent des immunoth\u00e9rapies ensemble\" \/>\n<meta property=\"og:description\" content=\"Une collaboration entre le l'EPFL et et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer par le biais de nouvelles immunoth\u00e9rapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-02T09:06:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-02T09:10:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"L’EPFL et Novochizol collaborent \u00e0 la conception d’immunoth\u00e9rapies plus efficaces\",\"datePublished\":\"2023-11-02T09:06:36+00:00\",\"dateModified\":\"2023-11-02T09:10:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\"},\"wordCount\":554,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Education\",\"Financing\",\"Oncology\",\"Personalized Medicine\",\"R&D\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\",\"name\":\"EPFL et Novochizol con\u00e7oivent des immunoth\u00e9rapies ensemble\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"datePublished\":\"2023-11-02T09:06:36+00:00\",\"dateModified\":\"2023-11-02T09:10:31+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Une collaboration entre le l'EPFL et et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer par le biais de nouvelles immunoth\u00e9rapies.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"La technologie de Novochizol transforme quantitativement des mol\u00e9cules lin\u00e9aires de chitosan en nanosph\u00e8res r\u00e9ticul\u00e9es de taille uniforme. | \u00a9 Novochizol\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L’EPFL et Novochizol collaborent \u00e0 la conception d’immunoth\u00e9rapies plus efficaces\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EPFL et Novochizol con\u00e7oivent des immunoth\u00e9rapies ensemble","description":"Une collaboration entre le l'EPFL et et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer par le biais de nouvelles immunoth\u00e9rapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/","og_locale":"fr_FR","og_type":"article","og_title":"EPFL et Novochizol con\u00e7oivent des immunoth\u00e9rapies ensemble","og_description":"Une collaboration entre le l'EPFL et et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer par le biais de nouvelles immunoth\u00e9rapies.","og_url":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-11-02T09:06:36+00:00","article_modified_time":"2023-11-02T09:10:31+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"L’EPFL et Novochizol collaborent \u00e0 la conception d’immunoth\u00e9rapies plus efficaces","datePublished":"2023-11-02T09:06:36+00:00","dateModified":"2023-11-02T09:10:31+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/"},"wordCount":554,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","keywords":["Biotech","Education","Financing","Oncology","Personalized Medicine","R&D","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/","url":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/","name":"EPFL et Novochizol con\u00e7oivent des immunoth\u00e9rapies ensemble","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","datePublished":"2023-11-02T09:06:36+00:00","dateModified":"2023-11-02T09:10:31+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Une collaboration entre le l'EPFL et et Novochizol vise \u00e0 r\u00e9volutionner le traitement du cancer par le biais de nouvelles immunoth\u00e9rapies.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","width":1180,"height":811,"caption":"La technologie de Novochizol transforme quantitativement des mol\u00e9cules lin\u00e9aires de chitosan en nanosph\u00e8res r\u00e9ticul\u00e9es de taille uniforme. | \u00a9 Novochizol"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/lepfl-et-novochizol-collaborent-a-la-conception-dimmunotherapies-plus-efficaces\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"L’EPFL et Novochizol collaborent \u00e0 la conception d’immunoth\u00e9rapies plus efficaces"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20979"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20979\/revisions"}],"predecessor-version":[{"id":20981,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20979\/revisions\/20981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20975"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}